This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), aims to develop a point-of-care HPV DNA test for cervical cancer screening in Mozambique. The total award is $585,943, with a performance period from September 1, 2024 to August 31, 2029. The key objectives are to: 1) Adapt existing extraction-free, multiplexed, isothermal nucleic acid amplification assays to detect 8...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to develop and evaluate an evidence-based, behavioral cervical cancer screening intervention for women living with HIV in Ghana. The $511,959 award to Baylor University will fund a hybrid effectiveness-implementation trial to integrate and scale up a home-based HPV self-sampling and communication model intervention called HOPE. The project seeks to...
The National Cancer Institute (NCI) awarded a 5-year, $706,365 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to The Trustees of Columbia University in the City of New York to implement the WHO-endorsed "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project aims to sustain implementation of the ISTAR approach and generate new data to inform effective and equitable...
The National Cancer Institute (NCI) awarded a 5-year, $629,068 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to Albert Einstein College of Medicine to conduct an implementation study of integrated human papillomavirus (HPV) self-sampling in HIV care centers in Ethiopia. The study aims to leverage the Project ECHO (Extension for Community Healthcare Outcomes) virtual learning platform to promote experience sharing and technical assistance across 5 hospitals to improve...
This $643,363 Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), will support a hybrid type III effectiveness-implementation trial to test best practices for deploying a "screen and treat" approach to cervical cancer screening using self-collected HPV DNA testing within HIV care and treatment facilities in Mozambique. The primary outcome is to increase the number of women screened and treated for...
The federal Project Grant award R01CA299475, titled "DEVELOPMENT OF SYSTEMS AND EDUCATION FOR CERVICAL CANCER PREVENTION (DOSE-CC)", is funded by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program) for $753,446. The grant aims to adapt and test an intervention to improve cervical cancer screening and follow-up in three diverse, underserved populations: urban inner city Blacks/Haitians, Hispanic immigrants, and Hawaiian natives/Pacific Islanders. The...
The National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $233,411 Project Grant to Pennsylvania State University to conduct a randomized controlled trial (RCT) titled "STORIES TO PREVENT (STOP) HPV CANCERS: A COMMUNICATION INTERVENTION TO INCREASE HPV VACCINATION AMONG DIVERSE POPULATIONS". The 2-year project, starting on April 1, 2025, will evaluate the impact of a narrative communication intervention delivered...
The National Cancer Institute (NCI) awarded a $1,245,116 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to Emory University to enhance cervical cancer screening and treatment for women living with HIV in Kenya. The project, titled "ENHANCING CERVICAL CANCER SCREENING AND TREATMENT IN WOMEN LIVING WITH HIV IN KENYA (ENHANCE LINKAGE)", will adapt and test evidence-based implementation strategies to overcome barriers to integrating cervical...
The National Cancer Institute (NCI) awarded a $962,560 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Basic Health International Inc., a non-profit organization based in Pittsburgh, Pennsylvania. The purpose of this 5-year grant (award date: September 18, 2024) is to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries...
This Project Grant award from the National Institutes of Health under the Trans-NIH Research Support program (CFDA 93.310) provides $1,382,625.00 to Purdue University to address cervical cancer disparities among people experiencing homelessness. The key objectives are to: 1) estimate cervical cancer screening coverage and associated factors among homeless communities in Indiana; 2) identify barriers and facilitators to screening, follow-up, and linkage to care; 3) assess the acceptability and...
PROGRESS: PREVENTION OF CERVICAL CANCER USING THE GENOTYPING AMPFIRE? SCREENING WITH SAME-DAY TREATMENT - PROJECT SUMMARY IN 2018, THE WORLD HEALTH ORGANIZATION (WHO) CALLED FOR ACTION TOWARDS ACHIEVING THE GLOBAL ELIMINATION OF CERVICAL CANCER. MEMBER STATES RATIFIED A STRATEGY FOR ACHIEVING THIS GOAL IN AUGUST 2020. THE WHO PLAN CALLS FOR AN AGGRESSIVE APPROACH OF VACCINATION, SCREENING, AND TREATMENT OF THE HUMAN PAPILLOMAVIRUS (HPV), THE SINGLE CAUSE OF CERVICAL CANCER. IN LOW- AND MIDDLE-INCOME COUNTRIES (LMIC), WHICH BEAR 90% OF THE INCIDENCE AND MORTALITY OF CERVICAL CANCER GLOBALLY, IT IS ESTIMATED THAT THESE GOALS WILL NOT BE REACHED UNTIL 2120 - A CENTURY FROM NOW. ONE WAY TO SHORTEN THIS TIMELINE IS THROUGH HPV SELF-SAMPLING AND IMMEDIATE TREATMENT FOR THOSE AT THE HIGHEST RISK OF DEVELOPING INVASIVE DISEASE. THIS WILL ONLY BE POSSIBLE THROUGH A LOW-COST AND EFFECTIVE TEST THAT IS EASY TO USE IN THE FIELD, COMBINED WITH TRIAGE STRATEGIES THAT CHANNEL WOMEN TO TREATMENT BUT AVOID UNNECESSARY PROCEDURES THAT DRAIN LIMITED RESOURCES. THE MODIFIED AMPFIRE HPV GENOTYPING TEST (ATILA BIOSYSTEMS, CA) IS A NEW TEST THAT IDENTIFIES 13 HIGH-RISK HPV TYPES AND STRATIFIES THEM BY ONCOGENIC RISK INTO FOUR GROUPS. AMPFIRE RELIES ON LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) RATHER THAN DNA EXTRACTION, THUS ALLOWING FOR SMALL-BATCH PROCESSING IN 1-2 HOURS AT A LOW COST PER SAMPLE. NO OTHER HPV TEST HAS THESE CHARACTERISTICS, WHICH ALLOW FOR THE DEVELOPMENT OF SAME-DAY SCREEN-AND-TREAT STRATEGIES THAT CAN TRIAGE WOMEN AT THE HIGHEST RISK, REDUCE LOSS TO FOLLOW-UP, AND DECREASE OVERTREATMENT. FURTHERMORE, THE MODIFIED AMPFIRE HAS DEMONSTRATED HIGH SENSITIVITY IN SELF-COLLECTED SAMPLES. THE PURPOSE OF THIS STUDY IS TO EVALUATE THE PERFORMANCE OF THIS IN THE DETECTION OF HIGH-GRADE PRECANCER (CERVICAL INTRAEPITHELIAL NEOPLASIA, GRADE 2 OR HIGHER, OR CIN2+). WE WILL ALSO PILOT A SAME-DAY SCREEN-AND-TREAT STRATEGY USING AMPFIRE AND AUTOMATED VISUAL ASSESSMENT (AVE), AN ARTIFICIAL INTELLIGENCE TRIAGE METHOD BASED ON AN ASSESSMENT OF CERVICAL IMAGES CAPTURED WITH AN ORDINARY SMARTPHONE. THUS, THIS STUDY WILL ACCOMPLISH THE FOLLOWING SPECIFIC AIMS: SPECIFIC AIM 1: TO ESTIMATE THE TEST PERFORMANCE OF SELF- AND PROVIDER- COLLECTED MODIFIED AMPFIRE SCREENING PLATFORM IN HONDURAS; SPECIFIC AIM 2: TO EVALUATE THE FEASIBILITY OF A SINGLE VISIT APPROACH USING A SELF-SAMPLED MODIFIED AMPFIRE SCREENING PLATFORM; SPECIFIC AIM 3: EVALUATE THE COST-EFFECTIVENESS OF THE SAME-DAY SCREEN-AND-TREAT APPROACH USING THE MODIFIED AMPFIRE TEST FOLLOWED BY TRIAGE WITH AUTOMATED VISUAL EVALUATION (AVE) VERSUS THE CURRENT STRATEGY IN HONDURAS.